Dokimes Life Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.42 Cr
- Revenue Growth 27.49%
- Profit Growth 26.36%
- Ebitda -27.67%
- Net Worth -14.24%
- Total Assets -7.78%
About Dokimes Life Science
Dokimes Life Science Private Limited (DLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 November 2018 (Six years and two months 29 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.42 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Satyawan Hatte and Manisha Hatte serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999MH2018PTC317391
- Company No.
317391
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Dokimes Life Science?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyawan Hatte  | Director | 26-Nov-2018 | Current |
| Manisha Hatte | Director | 26-Nov-2018 | Current |
Financial Performance of Dokimes Life Science.
Dokimes Life Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 27.49% increase. The company also saw a substantial improvement in profitability, with a 26.36% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dokimes Life Science?
Unlock access to Dokimes Life Science's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0
₹14.19 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.42 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Nov 2019 | State Bank Of India | ₹1.42 Cr | Satisfied |
How Many Employees Work at Dokimes Life Science?
Unlock and access historical data on people associated with Dokimes Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dokimes Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dokimes Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.